【复宏汉霖(02696.HK):注射用HLX43用于治疗复发/转移性食管鳞癌(ESCC)的 2期临床研究于中国境内完成首例患者给药】复宏汉霖(02696.HK)公布,近日,一项注射用HLX43(靶向PD-L1 抗体-新型DNA拓扑异构酶I抑制剂偶联药物)(HLX43)在复发/转移性食管鳞癌患者中开展的2期临床研究于中国境内(不包括中国港澳台地区,下同)完成首例患者给药。公司亦计划于条件具备后开展用于宫颈癌、肝细胞癌、鼻咽癌、头颈部鳞癌、非小细胞肺癌等潜在适应症治疗的相关2期临床试验。

金融界
10 Feb
复宏汉霖(02696.HK)公布,近日,一项注射用HLX43(靶向PD-L1 抗体-新型DNA拓扑异构酶I抑制剂偶联药物)(HLX43)在复发/转移性食管鳞癌患者中开展的2期临床研究于中国境内(不包括中国港澳台地区,下同)完成首例患者给药。公司亦计划于条件具备后开展用于宫颈癌、肝细胞癌、鼻咽癌、头颈部鳞癌、非小细胞肺癌等潜在适应症治疗的相关2期临床试验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10